JEFFREY ADELGLASS, M.D., F.A.C.S.
mICHELE rEYNOLDS, m.D., CPI
CLINICAL RESEARCH STUDIES
Dallas | ft. worth TEXAS
currently enrolling subjects for
PAID CLINICAL RESEARCH participation
What is the HUMMINGBIRD Study?
What makes the HUMMINGBIRD study vaccine different?
The study vaccine, NVX-CoV2373, differs from authorized vaccines in the way it is designed to provide COVID-19 virus protection. NVX-CoV2373 is a protein-based vaccine. Unlike mRNA vaccines, the study vaccine introduces your child's body to non-infectious parts (antigens) of the SARS-CoV-2 virus so their immune system can recognize the virus and fight it if they are ever exposed to the virus. This is similar to annual flu shots and other vaccines your child may have received for hepatitis B and human papillomavirus (HPV).
Now, researchers are evaluating it for children ages 6 months to 2 years.
To be eligible for this study, your child must:
• Be 6 months to 2 years of age
• Not have received a previous vaccine to protect against COVID-19
• Not have received any medications to prevent or treat COVID-19
This is not a complete list of eligibility criteria. The study doctor
will review the full entry criteria for this study with you.
Call (972) 746-2222 Now to Find Out if Your Child Qualifies for this Study
Do you have adolescent children ages 12 through 17? Visit that Page Here.